-Opioid receptors in the ventrolateral quadrant midbrain periaqueductal gray (vlPAG) contribute to extinction of conditioned fear. The present experiment studied whether fear extinction could be facilitated by infusions of a peptidase inhibitor that reduces catabolism of vlPAG enkephalins. Rats were trained to fear an auditory conditioned stimulus. Fear was then extinguished. Extinction training was preceded by infusions of vehicle or RB101(S), an inhibitor of enkephalin catabolising enzymes. RB101(S) dose dependently facilitated extinction as indexed by performance during extinction and on a drug-free test. This facilitation was not observed when RB101(S) was infused outside the vlPAG. These results confirm that vlPAG endogenous opioids contribute to fear extinction and show that extinction can be facilitated by manipulations that increase vlPAG opioid neuromodulation.
The fear acquired via pairings of a conditioned stimulus (CS) with an aversive unconditioned stimulus (US) can be reduced or extinguished by subsequent exposures to the CS in the absence of the US. Recent research has begun to identify the neural mechanisms for fear extinction. Extinction learning depends, at least in part, on amygdala N-methyl-D-aspartate (NMDA) receptor activation and consequent activation of the calcium/calmodulindependent protein kinase, protein kinase A, and the extracellular signal-regulated kinase/mitogen activated protein kinase pathways (for reviews see Davis, 2002; Myers & Davis, 2002; Maren & Quirk, 2004) .
The endogenous opioids contribute to fear extinction. Systemic administrations of opioid receptor antagonists impair fear extinction (McNally & Westbrook, 2003) and related associative errorcorrection phenomena (e.g., overexpectation; McNally, Pigg, & Weidemann, 2004a) . This contribution to fear extinction is mediated by opioid receptors in the ventrolateral column of the midbrain periaqueductal gray (vlPAG) but not other periaqueductal gray (PAG) columns (McNally, Pigg, & Weidemann, 2004b) . The -opioid receptor (MOR) subtype appears to be especially important for fear extinction (McNally, Lee, Chiem, & Choi, 2005) , and extinction is achieved via reductions in vlPAG cyclic adenosine monophosphate (cAMP) but not alterations in protein kinase A or mitogen-activated protein kinase (McNally et al., 2005) . The contribution of opioid receptors to fear extinction is not due to statedependent learning (McNally et al., 2004b; McNally & Westbrook, 2003) , interference with consolidation of the extinction memory (McNally & Westbrook, 2003) , or inhibition of the freezing conditioned response (McNally et al., 2004b; McNally & Westbrook, 2003) . One important prediction from this involvement of vlPAG opioids in fear extinction is that extinction should be enhanced by manipulations that increase vlPAG opioid neuromodulation. The present experiment tested this possibility.
The opioid peptides are derived from the proenkephalin, prodynorphin, and proopiomelanocortin precursors (McNally & Akil, 2002) . Each precursor gives rise to multiple active peptides capable of binding with high affinity to the MOR. The opioid peptides have a common Tyr-Gly-Gly-Phe sequence at their N termini, which is critical for binding to the opioid receptors (Akil et al., 1984) . This Tyr-Gly-Gly-Phe sequence is also a target for proteolysis by membrane bound zinc metallopeptidases (e.g., neutral endopeptidase [NEP, neprilysin, EC 3.4.24.11] and neutral aminopeptidase [APN, EC 3.4.11.2]; Roques, 2000; Turner, 2003) . These enzymes are located in the PAG (Noble et al., 2001) . Peptidase inhibitors can target and inhibit the enkephalin catabolising enzymes (Roques, 2000) . For example, administrations of inhibitors of enkephalin catabolism such as RB101(S) and RB3001 increase extracellular levels of enkephalin in the PAG and potentiate the behavioral effects of opioids (e.g., Le Guen et al., 2003; Roques, 2000) . The present experiment studied whether inhibiting enkephalin catabolising enzymes would facilitate the development of fear extinction. We chose to modulate the opioid system in this experiment by inhibiting opioid peptide metabolizing enzymes rather than by using an exogenous agonist for two reasons. First, only the former approach permits selective augmentation of the endogenous opioid peptide signal putatively generated during fear extinction. Second, the former approach, unlike the latter, is devoid of motivational effects and does not induce opiate dependence (Noble, Coric, Turcaud, Fournie-Zaluski, & Roques, 1994; Noble, Fournie-Zaluski, & Roques, 1993) . Rats were trained to fear an auditory CS via pairing with shock. Fear was then extinguished via nonreinforced presentations of the CS. Prior to extinction training rats received vlPAG infusions of 0 g, 0.5 g, or 5 g of RB101(S).
Method

Subjects
The subjects were experimentally naive, adult, male Wistar rats (250 -280 g) obtained from a commercial supplier (Gore Hill Research Laboratories, Sydney, Australia). Rats were housed in groups of 6 -8 in plastic cages maintained on a 12-hr light-dark cycle (lights on at 7 a.m.) with access to water and food ad libitum. The rats were handled (1-2 min per rat per day) for 3 days prior to surgery to habituate them to the experimenter. The procedures used were approved by the Animal Ethics Committee at the University of New South Wales.
Apparatus
Conditioning, extinction, and test were conducted in a set of four identical chambers (33 cm [height] ϫ 31 cm [length] ϫ 26 cm [width] ). The side walls and ceiling were made of aluminum, and the back and front walls were made of clear plastic. The side walls and ceiling were painted white, and the outside back wall was covered by white cardboard. The floor in each chamber consisted of stainless steel rods, 6 mm in diameter, spaced 15 mm apart (center to center). Each chamber stood 2 cm above a tray of cat litter. The chambers were cleaned with water, and the bedding underneath the chambers was cleaned between rats. These four chambers were located within separate compartments of a wooden cabinet. The door of each compartment was kept open to permit observation of the rat. A white fluorescent tube located in the ceiling illuminated the room. The US was a 1-s, 0.8 mA unscrambled AC 50-Hz shock from a constant-current generator that was delivered to the floor of each chamber. The current available to each floor could be adjusted using an in-line milliampere meter. The CS was a 10-s 82 dB (A scale; measured inside each conditioning chamber) 20-Hz clicker delivered through a speaker mounted in the ceiling of the experimental room. A video camera was mounted on the wall facing the boxes and connected to a VCR in an adjacent room.
Surgery and Histology
Rats were injected intraperitoneally with 1.3 ml/kg of the anesthetic ketamine at a concentration of 100 mg/ml and with 0.3 ml/kg of the muscle relaxant xylazine at a concentration of 20 mg/ml. Each rat was placed in the stereotaxic apparatus while maintaining the incisor bar at approximately 3.3 mm below horizontal to achieve a flat skull position. A 26-gauge guide cannula (internal diameter ϭ 0.24 mm; external diameter ϭ 0.46 mm; Plastics One, Roanoke, VA) was implanted into the right vlPAG. The tip of the guide cannula was positioned 5.5 mm below bregma through a hole drilled 0.0 mm anterior to and 0.8 mm lateral to lambda. We implanted cannula into only one hemisphere to reduce the possible extent of damage to the PAG and overlying blood vessels and to facilitate comparison with our previous work (McNally et al., 2004b (McNally et al., , 2005 . The guide cannula was fixed in position with dental cement and anchored to the skull by jeweler's screws. A dummy cannula was kept in the guide at all times except during microinjections. Immediately after surgery, rats were injected subcutaneously with 5 mg/kg Carprofen to provide postoperative pain relief, intraperitoneally with a prophylactic 0.3 ml dose of a 300 mg/ml solution of procaine penicillin and subcutaneously with 0.1 ml of 100 mg/ml cephazolin sodium. Rats were allowed 5 days to recover from surgery, during which time they were handled and weighed daily.
At the conclusion of the experiment, rats were given an overdose of sodium pentobarbital, and their brains were removed. Unfixed brains were sectioned coronally at 40 m through the vlPAG using a cryostat. Every fourth section was collected on a glass slide and subsequently stained with cresyl violet. Cannula placements were verified using the boundaries defined by Paxinos and Watson (1998) . The sections were examined under a microscope by a trained observer unaware of the subjects' group designations. The data of any rat were excluded from the statistical analysis if the cannula tip was outside the vlPAG or if there was evidence of extensive damage to the vlPAG.
Drugs and Microinjections
-oxopropyl]-l-phenylalanine benzyl ester) was dissolved in DMSO and then diluted by 50% in saline (0.9%; wt/vol) to obtain concentrations of 5 g/0.5 l and 0.5 g/0.5 l.
1 These solutions were made on the first day of microinjections and were kept at Ϫ20°C overnight. The 50% dimethylsulfoxide solution was used as vehicle for control infusions (0 g). All microinjections had a volume of 0.5 l. For microinjections, a 33-gauge microinjection cannula (internal diameter ϭ 0.10 mm; external diameter ϭ 0.20 mm; Plastics One, Roanoke, VA) was inserted into the guide cannula and connected to a 10 l glass syringe (Hamilton Company, Reno, NV) operated by an infusion pump (World Precision Instruments, Sarasota, FL). The microinjection cannula projected a further 1 mm ventral to the tip of the guide cannula. Drugs were infused over a 2 min, 40 s period, and the microinjection cannula was left in place for a further 1 min to permit diffusion of the injectate.
Procedure
On Day 0 of the experiment, rats were transported to the laboratory and placed in the conditioning chambers. Five hundred ninety seconds after placement in the chamber, rats received a 10-s presentation of the auditory CS that coterminated with delivery of the US. We used a 10-s CS during conditioning because our prior work indicated robust single trial fear conditioning to a 10-s CS. Rats were removed from the chamber 60 s after the US. Across Days 1-2, rats were transported to the laboratory and microinjected. All rats were placed in the conditioning chamber 5 min after microinjection. Extinction consisted of six 30-s presentations of the CS, with each presentation of the CS spaced 90 s apart. We used a 30-s CS presentation during extinction to facilitate comparison with prior work in our laboratory that focused on vlPAG opioid receptor contributions to fear extinction. The first CS was presented 120 s after placement in the chamber. On Day 3, rats were tested. The test consisted of four presentations of the 30-s CS, spaced 90 s apart. The first CS was presented 120 s after placement in the chamber.
Data Analysis
Performance during conditioning, extinction, and test were videotaped. The rats were scored every 4 s as either freezing (defined as the absence of all movement other than that required for breathing) or not freezing. The percentage of these observations scored as freezing was then calculated. The videotapes were scored by two observers, one of whom was unaware of group allocation. The interrater reliability (the correlation between each observer's ratings of percentage of observations scored as freezing) was .8. The data from the unaware observer was used for analysis by means of analysis of variance testing planned orthogonal contrasts. A multivariate approach to repeated measures was adopted (O'Brien & Kaiser, 1985) . The decision-wise error rate (␣) was controlled at .05. Figure 1 shows the location of microinjection tips for rats in this experiment. Ten animals were excluded from the experiment because of incorrect cannula placement. Thus, the final group sizes were Group 0 g (n ϭ 7), Group 0.5 g (n ϭ 5), and Group 5 g (n ϭ 7). The animals excluded from Group 5 g because of misplaced cannula were allocated to Group Misplaced and served as neuroanatomical controls for the effects of RB101(S). Figure 2A shows the mean levels of freezing during the 2 days of extinction training, averaged across each CS presentation (top), the average levels of freezing per day for each day of extinction training (bottom left), freezing during the 2 min immediately prior to the first CS on test (bottom middle), and the average level of CS freezing on test (bottom right). Inspection of the figure indicates that the training protocol reduced freezing by only a small amount in Group 0 g and that this extinction was facilitated, in a dose-dependent manner, by infusions of RB101(S).
Results
Histology
Behavior
The statistical analysis of the 2 min prior to the first CS presentation on Day 1 of extinction failed to detect any significant differences between Group 0 g and Group 0.5 g, F(1, 16) ϭ 1.9, or between Group 0 g and Group 5 g, F(1, 16) Ͻ 1. It is important to note that the statistical analysis of the 2 min prior to the first CS presentation on Day 2 of extinction did detect significant differences between Group 0 g and Group 0.5 g, F(1, 16) ϭ 11.7, p Ͻ 0.05, and between Group 0 g and Group 5 g, F(1, 16) ϭ 7.0, p Ͻ 0.05. Thus, Group 0 g showed significantly more pre-CS freezing (i.e., conditioned context fear) than the RB101(S) groups on Day 2 of extinction training but not on Day 1 of extinction training. This indicates that vlPAG microinjections of RB101(S) facilitated extinction of context fear.
Averaged across groups, levels of freezing decreased significantly between Day 1 and Day 2 of extinction training, F(1, 16) ϭ 15.8, p Ͻ 0.05. Averaged across days there was a significant effect of group so that freezing decreased as a linear function of RB101(S) dose, F(1, 16) ϭ 8.8, p Ͻ 0.05. It is important to note that there was also a Group ϫ Day interaction so that the decrease in freezing across Days 1 and 2 was a significant linear function of RB101(S) dose, F(1, 16) ϭ 15.9, p Ͻ 0.05. This effect of infusions of RB101(S) cannot be due to any tendency of those infusions to alter freezing per se because (a) there were no differences between groups in pre-CS freezing on Day 1; (b) there were no significant differences between Group 0 g and Group 0.5 g, F(1, 16) ϭ 1.2, or between Group 0 g and Group 5 g, F(1, 16) Ͻ 1), in average level of freezing on Day 1 of extinction; and (c) there was a significant spontaneous recovery (an increase in freezing) among rats in Group 5 g between the last CS presentation on Day 1 and the first CS presentation on Day 2, t(6) ϭ 2.44, p ϭ .05. The analysis of test day pre-CS freezing failed to detect any significant differences between Group 0 g and Group 0.5 g, F(1, 16) Ͻ 1, or between Group 0 g and Group 5 g, F(1, 16) ϭ 2.1. Therefore any differences to the CS in test performances cannot be due to differences in levels of pre-CS (i.e., conditioned context) freezing. The analysis of test day freezing to the CS revealed a significant difference between groups so that freezing to the CS on test decreased as a linear function of the dose of RB101(S) that was infused during extinction training, F(1, 16) ϭ 9.4, p Ͻ 0.05.
This effect of RB101(S) on fear extinction appeared to be specific to vlPAG. Three animals receiving infusions of 5 g RB101(S) were excluded from the above analysis because of misplaced cannula. Two misplaced cannulas were in dorsal raphe nucleus, and the remaining misplaced cannula was in the lateral PAG. We compared the performances of these animals (Group Misplaced) with those animals included in the analysis due to placements in vlPAG (Group vlPAG; Figure 2B ). Inspection of the figure suggests a significant difference in the effect of 5 g RB101(S) depending on the site of infusion. This was confirmed by the statistical analysis. Overall, Group vlPAG displayed significantly less freezing during extinction than Group Misplaced, F(1, 8) ϭ 13.8, p Ͻ 0.05. It is important to note that there was also a significant difference between these groups in CS freezing on test, F(1, 8) ϭ 6.5, p Ͻ 0.05, so that infusions of 5 g RB101(S) in Group vlPAG significantly increased extinction compared with infusions of 5 g RB101(S) Group Misplaced. It is worth emphasizing that the small number of animals with misplaced cannula does not permit the conclusion that lateral PAG and dorsal raphe were individually ineffective sites. Moreover, each misplaced cannula was bordered on vlPAG. Thus it is likely that some of the injectate in these animals affected vlPAG. The important point is that the effect of 5 g RB101(S) on fear extinction was significantly greater when cannulas were located in vlPAG.
Discussion
Opioid receptors in the mammalian central nervous system contribute to fear extinction (McNally et al., 2004a; McNally & Westbrook, 2003) . This contribution is mediated by opioid receptors in vlPAG and involves reductions in vlPAG cAMP (McNally et al., 2005) . This evidence for a role of vlPAG opioid receptors in fear extinction has been derived exclusively from experiments using opioid receptor antagonists. However, an important prediction from this research is that just as manipulations that reduce opioid neuromodulation reduce fear extinction, so too should manipulations that increase opioid neuromodulation in- ) and rats microinjected with 0.5 g or 5 g of the inhibitor of enkephalin catabolism RB101(S). A (bottom): Mean Ϯ SEM percentage of freezing during the first 2 min prior to CS onset on Day 1 and average freezing across the 2 days of extinction training as well as freezing during the drug-free test for the three groups described above. B: Mean Ϯ SEM percentage of freezing across the 2 days of extinction training as well as freezing during the drug-free test for rats microinjected with 5 g RB101(S) into the vlPAG (Group vlPAG) and rats microinjected with 5 g RB101(S) but excluded from the original analysis because of misplaced cannula (Group Misplaced). CS ϭ conditioned stimulus; vlPAG ϭ ventrolateral quadrant midbrain periaqueductal gray. crease fear extinction. The present experiment tested this possibility. The results showed that infusions of RB101(S), an inhibitor of the enkephalin degrading enzymes neutral endopeptidase and neutral aminopeptidase, facilitated the development of fear extinction. This facilitation was dose dependent and restricted to infusions in vlPAG. Infusions into adjacent structures (pooled data from lateral PAG or dorsal raphe nucleus) were significantly less effective. There was no evidence that facilitation of fear extinction by RB101(S) could be attributed to any tendency of RB101(S) to reduce freezing per se. Infusions of RB101(S) did not significantly reduce freezing in the pre-CS period on Day 1 of extinction training nor was there any effect of RB101(S) on freezing across the first few CS presentations on Day 1 of extinction training. Instead, the influence of RB101(S) emerged only after several CS presentations on Day 1 of extinction, so that, averaged across all six CS presentations on Day 1 of extinction training, all groups showed equivalent levels of freezing. Moreover, there was evidence for a significant increase in freezing among Group 5 g RB101(S) between the last CS presentation on Day 1 of extinction training and the first CS on Day 2 of extinction training. This return of fear is most parsimoniously interpreted as spontaneous recovery. Finally, facilitation of fear extinction was also observed when rats were tested in the absence of RB101(S). Thus, these results show for the first time that vlPAG infusions of an inhibitor of enkephalin catabolism enhance fear extinction.
We have suggested that during fear learning, endogenous opioid signaling through vlPAG MOR can be identified with an inhibitory feedback signal that regulates the amount learned on a conditioning trial. During nonreinforcement, or whenever the expected outcome of the conditioning trial exceeds the actual outcome (e.g., overexpectation; , vlPAG MOR activation generates an error signal that initiates fear extinction learning in another structure (e.g., amygdala or prefrontal cortex). According to this suggestion, infusions of opioid receptor antagonists into vlPAG impair extinction because they reduce MOR activation and consequently reduce the error signal that causes extinction learning. Expressed casually, the omission of the shock US is not surprising in animals extinguished under MOR antagonists. Conversely, in the present experiments, the infusions of RB101(S) into vlPAG facilitated extinction because they augmented the endogenous opioid signal putatively generated during fear extinction and consequently inflated the error signal. Expressed casually, the omission of the shock US was especially surprising for the animals extinguished under RB101(S). Several predictions regarding the effects of vlPAG infusions of RB101(S) clearly follow from this line of reasoning. For example, these infusions should facilitate the reduction in fear observed as a consequence of overexpectation training (e.g., McNally et al., 2004a) .
Irrespective of the fate of this account of the role of midbrain opioid receptors in regulating Pavlovian association formation, the present experiment confirms an important role for vlPAG endogenous opioids in fear extinction. This role could be of clinical interest. In Pavlovian fear conditioning in rats, manipulations that reduce opioid neuromodulation reduce fear extinction (e.g., McNally et al., 2004b McNally et al., , 2005 . In individuals suffering from simple phobia, manipulations that reduce opioid neuromodulation reduce the therapeutic benefit of exposure and systematic desensitization therapies (Arntz, Merkelbach, & de Jong, 1993; Egan, Carr, Hunt, & Adamson, 1988; Merluzzi, Taylor, Boltwood, & Götestam, 1991 ). The present experiment shows for the first time that manipulations that increase opioid neuromodulation increase fear extinction in rats. The effects of such manipulations on exposure therapies for anxiety disorders could be of interest.
